RBC Capital analyst Kennen MacKay maintained a Hold rating on Acceleron Pharma (NASDAQ:XLRN) on Thursday, setting a price target of $113, which is approximately 9.29% below the present share price of $124.57.
MacKay expects Acceleron Pharma to post earnings per share (EPS) of -$1.05 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Acceleron Pharma, with an average price target of $150.57.
The analysts price targets range from a high of $183 to a low of $113.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $24.76 million and a net profit of -$63.6 million. The company's market cap is $7.56 billion.
According to TipRanks.com, RBC Capital analyst Kennen MacKay is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.0% and a 55.93% success rate.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.